prikaz prve stranice dokumenta A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
  Download
PDF 1.22 MB
Scientific paper - Case study
A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
Journal of Clinical Medicine, 11 (2022), 10; 2779. https://doi.org/10.3390/jcm11102779
Turudić, Daniel; Milošević, Danko; Bilić, Katarina; Prohászka, Zoltán; Bilić, Ernest

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Turudić, D., Milošević, D., Bilić, K., Prohászka, Z. & Bilić, E. (2022). A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review. Journal of Clinical Medicine, 11. (10). doi: 10.3390/jcm11102779

Turudić, Daniel, et al. "A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review." Journal of Clinical Medicine, vol. 11, no. 10, 2022. https://doi.org/10.3390/jcm11102779

Turudić, Daniel, Danko Milošević, Katarina Bilić, Zoltán Prohászka and Ernest Bilić. "A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review." Journal of Clinical Medicine 11, no. 10 (2022). https://doi.org/10.3390/jcm11102779

Turudić, D., et al. (2022) 'A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review', Journal of Clinical Medicine, 11(10). doi: 10.3390/jcm11102779

Turudić D, Milošević D, Bilić K, Prohászka Z, Bilić E. A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review. Journal of Clinical Medicine [Internet]. 2022 May 14 [cited 2024 December 29];11(10). doi: 10.3390/jcm11102779

D. Turudić, D. Milošević, K. Bilić, Z. Prohászka and E. Bilić, "A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review", Journal of Clinical Medicine, vol. 11, no. 10, May 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:714954. [Accessed: 29 December 2024]

Metadata
Title (english)A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
AuthorDaniel Turudić
AuthorDanko Milošević
AuthorKatarina Bilić
AuthorZoltán Prohászka
AuthorErnest Bilić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pediatrics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pediatrics
Abstract (english)
Acute lymphoblastic leukemia (ALL) is considered a possible risk for the occurrence of thrombotic microangiopathies. We present a girl with pre-B ALL successfully treated according to the BFM ALL IC-2009 protocol on maintenance therapy followed by aHUS occurrence. This is the seventh case of HUS/aHUS on ALL maintenance therapy and the first with clearly documented eculizumab use in the early stage of aHUS/secondary TMA. Standard and additional parameters were used in aHUS monitoring alongside the reticulocyte production index adjusted for age (RPI/A) and the aspartate aminotransferase-to-platelet ratio index (APRI) as markers of hemolysis and rapid response following treatment. RPI/A and APRI are markers of bone marrow response to anemia serving as red blood cell vs. platelet recovery markers. Together they mark the exact recovery point of thrombotic microangiopathy and serve as a prognostic marker of eculizumab treatment success. During the 8-month treatment and 6-month follow-up, no recurrence of hemolysis, ALL relapse, or renal damage were observed. A systematic review of the literature revealed 14/312 articles; five children had aHUS before the onset of ALL, and two children had both diseases concurrently. At least 3/7 patients are attributed to aHUS, of whom 2/7 have renal damage. Potential undiagnosed/unpublished cases may be assumed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Clinical Medicine
Numberingvol. 11, no. 10, 2779
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm11102779
URN:NBNurn:nbn:hr:105:714954
Publication2022-05-14
Document URLhttps://www.mdpi.com/2077-0383/11/10/2779
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-12-14 07:56:01